These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30169973)

  • 1. Drug attributes associated with the selection of drugs for reimbursement: a pilot stated preferences experiment with Canadian stakeholders.
    Wranik WD; Skedgel C; Hu M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):59-69. PubMed ID: 30169973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts.
    Wranik WD; Jakubczyk M; Drachal K
    Value Health; 2020 Apr; 23(4):471-480. PubMed ID: 32327164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best-worst scaling approach.
    Wranik WD; Székely RR; Mayer S; Hiligsmann M; Cheung KL
    J Med Econ; 2021; 24(1):846-856. PubMed ID: 34162282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?
    McDonald H; Charles C; Elit L; Gafni A
    Pharmacoeconomics; 2015 Mar; 33(3):235-41. PubMed ID: 25424496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
    Maynou L; Cairns J
    Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
    Wranik WD; Gambold L; Peacock S
    Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian Public Preferences for the Funding of New Health Technologies: A Comparison of Discrete Choice and Profile Case Best-Worst Scaling Methods.
    Whitty JA; Ratcliffe J; Chen G; Scuffham PA
    Med Decis Making; 2014 Jul; 34(5):638-54. PubMed ID: 24713695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?
    Shmueli A
    Isr J Health Policy Res; 2017; 6():20. PubMed ID: 28469840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
    Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
    Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
    Rocchi A; Mills F
    J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choice Experiments to Quantify Preferences for Health and Healthcare: State of the Practice.
    Mühlbacher A; Johnson FR
    Appl Health Econ Health Policy; 2016 Jun; 14(3):253-66. PubMed ID: 26992386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
    Enzing JJ; Himmler S; Knies S; Brouwer WBF
    Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY; Rawson NSB
    Curr Oncol; 2024 Sep; 31(9):5599-5607. PubMed ID: 39330042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.